...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Diabetes, obesity & metabolism >Effects of the sibutramine therapy on pulmonary artery pressure in obese patients.
【24h】

Effects of the sibutramine therapy on pulmonary artery pressure in obese patients.

机译：西布曲明治疗对肥胖患者肺动脉压的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIM: Obesity is a major global public health problem. Previous drugs (dexfenfluramine and fenfluramine) used for the treatment of obesity have been withdrawn due to various cardiac side effects. Sibutramine is an anti-obesity agent. The purpose of this study was to assess cardiac valve disease and pulmonary artery pressure (PAP) of the patients who used once daily doses of sibutramine. METHODS: One hundred and six obese patients (51 men and 55 women) determined to have minimal tricuspid regurgitation (TR) on echocardiographic examination were included in the study. All patients had a complete physical examination, complete blood count and measurement of lipid parameters, and echocardiography was performed by which cardiac valves and PAP were evaluated. After the mean duration of 24-week of follow up, all examinations were repeated for each patient. RESULTS: The drug was well tolerated by all patients for the follow-up period. A significant weight loss was recorded in all patients compared to the baseline values (93.1 +/- 9.6 kg vs. 85.8 +/- 7.7 kg, p < 0.001). Blood pressures and heart rate of the patients increased compared to the baseline measurements (systolic 122.3 +/- 8.5 vs. 124 +/- 10.2 mmHg, p = 0.128, diastolic 79.3 +/- 4.7 vs. 80 +/- 5.7 mmHg, p = 0.42 and heart rate 79.5 +/- 6.5 vs. 85 +/- 5.7 beats/min, p < 0.001). Echocardiographically determined aortic or mitral valve dysfunction appeared in none of the patients. PAP lightly increased after the treatment but the difference between pre and post-treatment values was not found statistically significant (14.7 +/- 1.8 vs. 16.3 +/- 1.6 mmHg, p = 0.06). CONCLUSIONS: A 24-week treatment with sibutramine does not affect heart valves and pulmonary artery pressure.
机译：目的：肥胖是全球主要的公共卫生问题。由于各种心脏副作用，已经取消了用于治疗肥胖症的先前药物（右芬氟拉明和芬氟拉明）。西布曲明是抗肥胖药。这项研究的目的是评估每天使用一次西布曲明的患者的心脏瓣膜疾病和肺动脉压（PAP）。方法：该研究包括经超声心动图检查确定为三尖瓣关闭不全（TR）的106例肥胖患者（51例男性和55例女性）。所有患者均进行了全面的体格检查，全血细胞计数和血脂参数测量，并进行了超声心动图检查，以评估心脏瓣膜和PAP。平均随访24周后，对每位患者重复所有检查。结果：在随访期间所有患者对药物的耐受性良好。与基线值相比，所有患者的体重均显着减少（93.1 +/- 9.6 kg vs. 85.8 +/- 7.7 kg，p <0.001）。与基线测量值相比，患者的血压和心率增加（收缩期122.3 +/- 8.5 vs. 124 +/- 10.2 mmHg，p = 0.128，舒张期79.3 +/- 4.7 vs. 80 +/- 5.7 mmHg，p = 0.42，心率79.5 +/- 6.5 vs. 85 +/- 5.7次/分钟，p <0.001）。超声心动图确定的主动脉或二尖瓣功能障碍均未见患者。治疗后PAP轻度升高，但未发现治疗前和治疗后值之间的差异具有统计学意义（14.7 +/- 1.8 vs. 16.3 +/- 1.6 mmHg，p = 0.06）。结论：西布曲明治疗24周不会影响心脏瓣膜和肺动脉压。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号